Enasidenib vs conventional care in older patients with late-stage mutant-<i>IDH2</i> relapsed/refractory AML: a randomized phase 3 trial
Stéphane de Botton(Université Paris-Sud), Courtney D. DiNardo(The University of Texas MD Anderson Cancer Center)
Cited by 110
Related Papers
An activating mutation in the <i>CSF3R</i> gene induces a hereditary chronic neutrophilia
|The Journal of Experimental Medicine|2009|81